Skip to main content
Menu

Posts tagged with "Patents and IP"

  • Infectious Diseases

    Unclean Hands?

    Well, this doesn’t look good: reports are that the Gilead/Merck hepatitis C inhibitor patent case may be heading back into court under accusations that one of Merck’s patent lawyers (a former med-chemist) lied under oath. The scientist involved, Phil Durette, already had some problems during his testimony the first time around: At tria… Read More
  • Business and Markets

    The Impact of Various Countries on Biopharma – Or Not

    Here’s a report looking at biopharma by country, and ranking countries based on how good an environment they provide for the industry. The three big criteria are how much their governments spend on R&D, specifically life sciences and medical R&D, how closely they regulate pharmaceutical prices, and how strong their intellectual proper… Read More
  • Aging and Lifespan

    The Samumed Story

    Biopharma can be a weird place. Breakthroughs happen, although not as often as the press releases would have everyone believe, and we certainly don’t always see them coming. So when word comes of some amazing new therapy, you can’t dismiss it out of hand, because amazing new therapies do arrive from time to time, and… Read More
  • Business and Markets

    Codexis Says They’ve Been Ripped Off

    I mentioned enzyme engineering briefly the other day, and that, of course, is where companies like Codexis make their living. They made a big splash with Merck a few years ago, and are continuing to work with a variety of partners to industrialize tricky enzymatic transformations. Well, now they’re accusing a former employee of Pfizer… Read More
  • Drug Prices

    Generics Get Cheaper, As They Should

    Here’s a useful perspective from Alex Tabarrok at Marginal Revolution: several recent studies have concluded that, over the last several years, generic drug prices as a whole have continued to decrease. That’s how it’s supposed to be: all those prescription drugs whose prices seem ridiculous are (eventually) doomed. They’ll… Read More
  • Drug Prices

    The AG of Massachusetts Has No Chance Against Gilead

    Drug prices too high? Why not just have the state Attorney General’s office set them for you? That’s what I’m taking away from this story. Maura Healy, AG of Massachusetts, is firing a warning shot at Gilead over the pricing of their HepC drugs. Her office is apparently considering whether Gilead is engaging in an… Read More
  • Biological News

    Why This CRISPR Article, and Why Now?

    I mentioned the CRISPR patent fight here the other day, but that’s not the only front where conflict has broken out. Cell has published a piece by Eric Lander called “The Heroes of CRISPR” that’s attracting some controversy, for example. The problem is that Lander (at the Broad Institute) is unlikely to be a completely… Read More
  • Biological News

    The CRISPR Interference Case

    Now this is going to be a complicated process indeed: the CRISPR patent dispute is now officially an interference proceeding at the USPTO. This was always a likely path – the main other one would have been for the parties involved to have negotiated some sort of cross-licensing agreement, but that doesn’t seem to be… Read More
  • Patents and IP

    How Do You Find A New Compound to Patent?

    I recently had a question from an interested reader, who’s outside of medicinal chemistry, wondering about how we find room to work in patent space. From his viewpoint, there seemed to be many areas that were so worked over that he found it had to see how any new project could make headway, or be… Read More
  • Patents and IP

    The Problem With Patents

    Fair warning: this is a post about patents and IP. I say that because in the past, I’ve practically been able to see the readers fleeing in real time when such things come up. Two or three of them in a row, and there would probably be nobody left around at all. But it’s a… Read More
123...